Background Amyloid transthyretin (ATTR) amyloidosis is a rare, life-threatening disease frequently manifesting with ...

An analysis of major depressive disorder, covering diagnostic criteria, prevalence statistics across demographics, and ...

Patients with primary biliary cholangitis and moderate-to-severe pruritus who received seladelpar over 6 months experienced a ...

Nirogacestat therapy shows sustained benefits, including tumor shrinkage and durable responses, in long-term treatment of ...

Dupilumab, a fully human monoclonal antibody, inhibits the signaling of the interleukin 4 (IL-4) and IL-13 pathways.

First-line treatment of advanced acral melanoma with the PD-1 inhibitor toripalimab (Loqtorzi) resulted in a small but ...

Chronic myeloid leukemia highlights from ASH 2025 include data on nilotinib vs imatinib, asciminib in second line, somatic ...

Piqray plus Faslodex significantly improved PFS in PIK3CA-mutated, hormone receptor-positive, HER2-negative advanced breast ...

“Gedatolisib plus Faslodex, with or without Ibrance, represents a potential new standard of care for patients with hormone ...

Al-Gahtani, S. (2026) Review of Literature Investigating the Correlation between Prevalence of Risk Factors Associated with ...

A conserved signaling axis linking Drosophila adipose tissue to nephrocyte function reveals how obesity can drive kidney dysfunction and points to new opportunities for therapeutic intervention.

Primary Hydrogen Corp. engages in the acquisition, exploration, and development of mineral properties. The company was founded on July 27, 2020 and is headquartered in Vancouver, Canada.